Program/Target Prog/Tgt
Indication Ind
Discovery Discov
Preclinical Preclin
Phase 1 Ph 1
Phase 2 Ph 2
Current Status Status
OKI-219
Breast cancer
OKI-219
PI3KαH1047R
selected inhibitor
Breast cancer
PIKture-01 Trial
Phase 1
enrolling
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2-Targeted Therapy in Participants with Advanced Breast Cancer. Additional information about PIKture-01 may be found at www.ClinicalTrials.gov, using Identifier NCT06239467
OKI-TBD
Breast cancer
OKI-TBD
PI3KαH1047X (next gen)
selected inhibitor
Breast cancer
Candidate
selection
OKI-TBD
Breast cancer
OKI-TBD
PI3Kα E542K, E545K
selected inhibitor
Breast cancer
Active
discovery